Program
tapinarof
Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.
Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.
Drug pageTapinarof: every studyMany companies study it; this page follows only the 25 they lead. All 34 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 121 open or running | phase 4since Dec 26, 2022 | May 16, 2019 | Aug 2027phase 3 · NCT07265479 |
| GlaxoSmithKlineits history only | 80 open or running | phase 3since Jun 27, 2017 | Oct 31, 2013 | none ahead |
| Welichem Biotech | 30 open or running | phase 2since Feb 3, 2009 | Feb 3, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | none ahead |
Also a collaborator on its studies: Teva Pharmaceuticals, IQVIA Biotech, PPD DEVELOPMENT, LP, Q2 Solutions and iCardiac Technologies.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Welichem Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 3, 2009First study: phase 2 study in Dermatitis, AtopicFirst studyNCT00837551 · 36 enrolled · Canada
- Apr 1, 20102 phase 2 studiesNCT01098734, NCT01098721
- Dec 9, 2016Named tapinarofINNProposed as its International Nonproprietary Name in WHO's List 116 · before, WBI-1001
TargetBeta
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule
Studies
All 3 Welichem Biotech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01098734Dermatitis, Atopic · Canada | 2 | Completed | Oct 2010 | 148 |
| NCT01098721Psoriasis | 2 | Completed | Sep 2010 | 61 |
| NCT00837551Dermatitis, Atopic · Canada | 2 | Completed | Jun 2008 | 36 |
How it is read
Names in the registry
- “Tapinarof cream, 1%”, 4 entries
- “tapinarof cream, 1%”, 4 entries
- “WBI-1001”, 3 entries
- “Tapinarof”, 2 entries
- “GSK2894512 1% Cream”, 2 entries
Codes read as this program: GSK2894512.
Conditions, from the studies’ own filings
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Skin Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.